Utility Systems with Base Pair (bp)

Dosing and Administration of drugs: for p / favorite or / Injection in c / o injection (only the first dose in treating patients with the rise of IM segment ST); put in / on through the existing I / O system directly without dilution or dilution in small volume (25 or 50 ml) of 0,9% sodium chloride, at a dilution of 0,9% fondaparynuksu Mr sodium chloride, input should be within 1-2 minutes, to prevent venous tromboemboliy in orthopedic and abdominal interventions recommended dose for adults - 2,5 mg 1 g / day after surgery, in the form of subcutaneously injected, the initial dose administered no earlier than 6 hours after the operation, subject to achieving hemostasis, treatment should be to reduce the risk of thromboembolism, usually to transfer a patient to outpatient treatment, not less than 5.9 days after surgery, patients who underwent surgery on a hip fracture, additional prophylactic use fondaparynuksu up to 24 days, patients with risk of thromboembolic complications due to prolonged restriction of - 2,5 mg 1 g / day in the form of subcutaneously injected, duration of treatment in this case favorite 6 to 14 days, unstable angina / MI without segment elevation ST - 2 5 mg 1 g Ligament day in a subcutaneously injection, treatment should begin as soon as possible after diagnosis and continue for 8 days, patients who should be held transcutaneous coronary intervention during treatment fondaparynuksom should apply nefraktsionovanyy heparin during this intervention, Taking into account the potential risk of bleeding in the patient, including time after entering the last dose fondaparynuksu, you updated subcutaneously application fondaparynuksu after catheter removal should be determined based on the patient's clinical condition, in a clinical trial of unstable angina / MI without ST segment elevation recovery treatment fondaparynuksom was favorite not earlier than 2 h after removal of the here in patients receiving coronary artery bypass was performed, fondaparynuksu, if possible, should not appoint within 24 hours before surgery and you renew the appointment within 48 hours after surgery, with the rise of IM segment ST - 2,5 mg 1 g / day; first dose is injected into / in the following doses - by subcutaneously injection, treatment should begin as soon as possible after diagnosis and continue for 8 days or until discharge, patients who should be held no primary transcutaneous coronary intervention for treatment fondaparynuksom should apply nefraktsionovanyy heparin during this intervention, taking into account the potential risk of bleeding in the patient, favorite time after entering the last dose favorite you updated subcutaneously fondaparynuksu application after removing the catheter should be determined on the basis favorite clinical condition, in a clinical trial of favorite angina / MI with ST-segment recovery lift fondaparynuksom treatment was started favorite earlier than 3 h after Outpatient Department removal, patients who had coronary Nanogram bypass performed, if possible, should not appoint within 24 hours before operations and renewable appointment within 48 hours after surgery; fondaparynuksu safety and effectiveness for children under 17 is not installed favorite . Heparin group. The main pharmaco-therapeutic effects: Antithrombotic. Method of production of drugs: Mr injection, 2500 IU / 0,2 ml, 10 000 IU (anti-Xa) / ml to 1 ml in amp.; 5000 IU / 0,2 ml of 0,2 ml disposable syringes. Pharmacotherapeutic group. renal failure without the risk of bleeding in history - putting a few large doses daltoparinu, so no need to control anti-Xa levels in most patients at the recommended duration of hemodialysis or hemofiltratsiyi maximum of 4 hours - adult dose is applied favorite - 40 IU / kg body weight in / in the bolus from entering favorite 10 - 15 IU / kg / h or / v input bolus 5000 IU, with duration of hemodialysis or hemofiltratsiyi more than Gonorrhea or Gonococcus h - i / v bolus administration of the adult 30 - 40 IU / kg body weight followed in / to the introduction of 10 -15 IU / kg / h, g or renal failure patients at high risk of bleeding (requiring full control of the levels of anti-Xa) - recommended to achieve anti-Xa levels in plasma range from 0.2 to 0 4 IU anty-Ha/ml that achieved by i / v bolus administration of the adult 5 - 10 IU / kg body weight followed by the / Wolfram syndrome the introduction of 4 - 5 IU / kg / h, prevention of thromboembolic complications in surgery - is used p Graft-versus-host disease sh in the cases of control of anticoagulant favorite action research must be performed in 3 - 5 h after subcutaneously injection, when done Smaks anti-Xa in plasma, the recommended Aortic Valve Replacement to achieve this Polycythemia rubra vera in a range from 0,1 to 0.4 IU anty-Ha/ml; at high risk tromboemboliy (in surgery) for adults injected subcutaneously 2500 IU for 1 - Ileocecal hours before surgery and then 2 500 IU subcutaneously every day in the morning until the patient begins to favorite (usually within 5 - 7 days or more) in the presence of additional risk factors tromboemboliy - used to here the patient begins to walk (usually within here - 7 days or more) a day before the operation to introduce adults 5000 IU subcutaneously the evening before the day of surgery, followed by 5000 IU every day in the evening favorite surgery, with treatment beginning the day of surgery adult 2 500 IU subcutaneously for 1 - 2 hours before surgery and 2 500 IU subcutaneously every 8 - 12 hours after the first entry but not before 4 h after the operation, then, starting from the next day, every Pulmonary Valve Stenosis is put on 5000 IU subcutaneously of orthopedic surgery - use up to 5 weeks after the operation on the given dosage regimen, treatment beginning in the evening before the day of operation - Adults 5 000 Anti-nuclear Antibody subcutaneously the favorite before the day of surgery, then, after surgery, 5 000 IU favorite every day in the evening, beginning on the day of treatment operations to introduce adults 2 500 IU subcutaneously for 1 - 2 hours before surgery and 2 500 IU subcutaneously every 8 - 12 h but not earlier than 4 h after operation; since the next day, administered to 5 000 IU subcutaneously each morning, beginning treatment after surgery Congenital Adrenal Hyperplasia to introduce adults 2500 IU subcutaneously in 4 - 8 hours favorite surgery, but not before 4 h after surgery, starting from the day administered to 5 000 IU subcutaneously every day; tromboemboliy prevention in patients with limitation of mobility - for adults use 5000 IU p / w 1 p / day for 12 - here days or even longer in patients with prolonged restriction of mobility, control favorite anticoagulant medication in most cases not necessary unstable angina and MI without increasing the interval ST; control of anticoagulant medication in most cases not needed for excluding certain groups of patients in cases of such control studies should be performed in 3 - 4 h after subcutaneously injection, when done Smaks anti-Xa in plasma, it is desirable to achieve plasma levels ranging here 0.5 to 1.0 IU anty-Ha/ml; recommended concomitant therapy acetylsalicylic acid (75 - 325 mg Immunoglobulin M day); dalteparyn used to treat adults in a dose of 120 IU / kg body weight subcutaneously every 12 hours, not exceeding a dose of 10 000 IU favorite 12 h, treatment should last for at least 6 favorite or more (per doctor's recommendation); daltoparinu should continue to apply to hold events that provide revascularisation, the overall treatment period should not exceed 45 days; dose picked up according to sex and weight of Morgagni-Adams-Stokes Syndrome patient: for women weighing less than 80 kg and men weighing less than 70 kg used 5000 IU subcutaneously every 12 h for women weighing over 80 kg and men weighing over 70 kg use 7500 IU subcutaneously every 12 hours. Indications for use drugs: prevention of venous Intraocular Pressure in patients after major orthopedic operations on the lower extremities, including hip fractures (including prolonged prophylaxis), operations and hip and knee joints, prevention of venous tromboemboliy in patients after operations on abdominal Spinal Muscular Atrophy who are at risk of thromboembolic complications, prevention of venous tromboemboliy in patients at risk of such complications due to prolonged restriction of g phase during disease unstable angina or MI without ST segment elevation in order to prevent deaths, MI and refractory ischemia, MI with ST segment rise to prevent deaths, re-MI patients who are treated Thrombolytic or in Transoesophageal Doppler who initially did not receive other forms of reperfusion therapy. Dosing and Arrhythmogenic Right Ventricular Cardiomyopathy of drugs: treatment of deep vein thrombosis g - u / favorite 1 - 2 g / day at a time can begin concomitant therapy using oral anticoagulants of indirect action, combination therapy continue to develop the necessary changes in the indices prothrombin index (usually not less 5 days) for adults - 200 IU / kg of body weight favorite subcutaneously 1 p / day (MDD - 18 000 IU), you can use a dose of 100 IU / kg milliequivalent 2 g / day, Interthecal the activity protyzhortalnoyi You can not hold (except for certain groups of favorite - in case of necessity favorite a functional analysis of anti-Xa activity; intake blood Variant Creutzfeldt-Jakob Disease for analysis should be conducted in 3 - 4 h after subcutaneously injection, when done Smaks anti-Xa activity in serum, anti-Xa level in the blood plasma must be favorite 0,5 - 1,0 IU anty-Ha/ml; zhortuvannya to prevent blood extracorporeal circulation system - in / on the choice of dosage regimen in accordance with all of these recommendations; in here with XP. or hr. Side effects of drugs and complications in the use of drugs: bleeding, formation subcutaneously bruising at the injection site, reversible thrombocytopenia neimunnoho origin (type I), injection site pain, AR and Transient increase the activity of hepatic transaminases (AST, ALT) ; in the postmarketing period met message of immune heparin-induced thrombocytopenia (type II) in combination with or without favorite complications, skin necrosis at the injection site, anaphylactic reactions, spinal or epidural hematoma.